Ask us a question
520 547-3440
[email protected]
Subscribe
Critical Path Institute
Home
About
HOW WE OPERATE
Timeline
People
FAQ
Employment
Annual Reports
Programs
Sharing Knowledge that Leads to Innovation
BmDR
Biomarker Data Repository
CAMD
Coalition Against Major Diseases
CFAST
Coalition for Accelerating Standards & Therapies
CPP
Critical Path for Parkinson’s
CPTR
Critical Path to TB Drug Regimens
DCC
Data Collaboration Center
D-RSC
The Duchenne Regulatory Science Consortium
ePRO Consortium
Electronic Patient-Reported Outcome Consortium
INC
International Neonatal Consortium
MSOAC
Multiple Sclerosis Outcome Assessments Consortium
PKD
Polycystic Kidney Disease Outcomes Consortium
PRO Consortium
Patient-Reported
Outcome Consortium
PSTC
Predictive Safety Testing Consortium
PTC
Pediatric Trials Consortium
T1D
Type 1 Diabetes Consortium
TB-PACTS
TB-Platform for Aggregation of Clinical TB Studies
TTC
Transplant Therapeutics Consortium
Successes
News & Events
Events
News
Videos
Publications
Presentations
Press Releases
Contact
Donate
News
Home
>
News & Events
>
Presentations
>
PRO Consortium
>
Expanding the Measurement of Treatment Benefit in Rheumatoid Arthritis (RA): The Role of the Patient-Reported Outcome Consortium’s RA Working Group
Presentations
November 3, 2012
PRINT
PDF
Expanding the Measurement of Treatment Benefit in Rheumatoid Arthritis (RA): The Role of the Patient-Reported Outcome Consortium’s RA Working Group
Share this
x
